Spots Global Cancer Trial Database for carcinoma, bronchogenic
Every month we try and update this database with for carcinoma, bronchogenic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT04222972 | RET-fusion Non ... Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Disea... Head and Neck N... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Germ... Neoplasms, Nerv... | Pralsetinib Carboplatin Cisplatin Pemetrexed Pembrolizumab Gemcitabine Paclitaxel Nab-Paclitaxel | 18 Years - | Hoffmann-La Roche | |
| Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy | NCT02984761 | Lung Neoplasm | Stereotactic Ra... Anatomic Pulmon... | 18 Years - | VA Office of Research and Development | |
| Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer | NCT01058785 | Lung Neoplasm Carcinoma, Bron... | Lucanix | 18 Years - | NovaRx Corporation | |
| A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC | NCT03134872 | Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Lung Diseases Respiratory Tra... Neoplasms by Si... Neoplasm, Bronc... Carcinoma, Bron... | SHR-1210 Carboplatin Pemetrexed | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC | NCT03085069 | Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Lung Disease Respiratory Tra... Neoplasm, Bronc... Carcinoma, Bron... | SHR-1210 | 18 Years - 80 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC | NCT03134872 | Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Lung Diseases Respiratory Tra... Neoplasms by Si... Neoplasm, Bronc... Carcinoma, Bron... | SHR-1210 Carboplatin Pemetrexed | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) | NCT01999985 | Lung Cancer Non-small Cell ... | Dasatinib - 1A Afatinib - 1A Dasatinib - 1B Afatinib - 1B | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors | NCT00413322 | Tumor | belinostat 5-Fluorouracil ... | 18 Years - | Valerio Therapeutics | |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | NCT03157128 | Non-Small Cell ... Medullary Thyro... Colon Cancer Any Solid Tumor | LOXO-292 | 12 Years - | Eli Lilly and Company | |
| A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer | NCT01574222 | Non-Small Cell ... | autologous dend... | 21 Years - | VA Office of Research and Development | |
| A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection | NCT03083743 | Non-small-cell ... | Recombinant hum... Placebo | 18 Years - 75 Years | Shanghai Gebaide Biotechnology Co., Ltd. | |
| Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer) | NCT03053297 | Carcinoma, Non-... | Patient Reporte... | 18 Years - | AstraZeneca | |
| A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC | NCT03085069 | Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Lung Disease Respiratory Tra... Neoplasm, Bronc... Carcinoma, Bron... | SHR-1210 | 18 Years - 80 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC) | NCT00102505 | Non-Small-Cell ... Carcinoma, Bron... | Motexafin Gadol... | 18 Years - | Pharmacyclics LLC. | |
| Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer | NCT05297734 | End of Life Cancer | Receive technol... Receive redesig... | 21 Years - | Stanford University | |
| A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy | NCT05941897 | Advanced or Met... | Ceralasertib Durvalumab | 18 Years - | AstraZeneca | |
| Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer | NCT02904954 | Carcinoma, Non-... | Durvalumab Durvalumab plus... | 18 Years - | Weill Medical College of Cornell University | |
| New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy | NCT04564157 | Non-Small Cell ... Adjuvant Chemot... | Carboplatin Paclitaxel Nivolumab | 18 Years - | Fundación GECP | |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | NCT04862780 | Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla... | BLU-945 osimertinib | 18 Years - | Blueprint Medicines Corporation | |
| New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy | NCT04564157 | Non-Small Cell ... Adjuvant Chemot... | Carboplatin Paclitaxel Nivolumab | 18 Years - | Fundación GECP | |
| The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial | NCT03402048 | Stage IV, NSCLC Lung Neoplasms Bronchial Neopl... Carcinoma, Bron... Lung Diseases Neoplasms Respiratory Tra... Respiratory Tra... Thoracic Neopla... | Carboplatin Gemcitabine Pemetrexed Docetaxel Vinorelbine | 70 Years - | University of Turin, Italy | |
| Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer | NCT03331588 | Lung Neoplasms Thoracic Surger... Carcinoma, Non-... Lung Diseases Carcinoma, Bron... Thoracic Neopla... | Subxiphoid unip... Intercostal uni... | 18 Years - 80 Years | Shanghai Pulmonary Hospital, Shanghai, China | |
| A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer | NCT01574222 | Non-Small Cell ... | autologous dend... | 21 Years - | VA Office of Research and Development | |
| Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients | NCT04512430 | Non Small Cell ... EGFR Gene Mutat... | Atezolizumab Bevacizumab Carboplatin Pemetrexed | 18 Years - | Fundación GECP | |
| Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors | NCT00413322 | Tumor | belinostat 5-Fluorouracil ... | 18 Years - | Valerio Therapeutics | |
| Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors | NCT00413322 | Tumor | belinostat 5-Fluorouracil ... | 18 Years - | Valerio Therapeutics | |
| Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer | NCT02288026 | Stage IA Non-sm... Adenocarcinoma ... Squamous Cell L... | 60 Years - 80 Years | Capital Medical University | ||
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | NCT05153408 | Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR C797S EGFR C797A EGFR L858R EGFR Exon 19 De... EGFR Gene Mutat... EGF-R Positive ... EGFR Mutation R... EGFR Activating... Thoracic Neopla... Antineoplastic ... Protein Kinase ... EGFR C797G EGFR C797X Non Small Cell ... | BLU-701 osimertinib carboplatin pemetrexed | 18 Years - | Blueprint Medicines Corporation | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | NCT03037385 | RET-altered Non... Medullary Thyro... RET-altered Pap... RET-altered Col... RET-altered Sol... Lung Neoplasm Carcinoma, Non-... Thyroid Disease... Thyroid Neoplas... Thyroid Cancer,... Carcinoma, Neur... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Endocrine Syste... Endocrine Gland... Head and Neck N... Adenocarcinoma,... Adenocarcinoma Carcinoma Neoplasms, Glan... Neoplasms by Hi... Neuroendocrine ... Neuroectodermal... Neoplasms, Germ... Neoplasms, Nerv... Colonic Neoplas... Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... | pralsetinib (BL... | 18 Years - | Hoffmann-La Roche | |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer | NCT01574222 | Non-Small Cell ... | autologous dend... | 21 Years - | VA Office of Research and Development | |
| (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | NCT05241873 | Lung Neoplasm M... Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... EGFR Exon 20 Mu... EGFR Exon 20 In... EGFR Activating... Antineoplastic ... Metastatic Lung... Brain Metastase... EGFR-mutated NS... EGFR Atypical M... | BLU-451 Carboplatin Pemetrexed | 18 Years - | Blueprint Medicines Corporation | |
| Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy | NCT02984761 | Lung Neoplasm | Stereotactic Ra... Anatomic Pulmon... | 18 Years - | VA Office of Research and Development | |
| A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC | NCT03085069 | Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Lung Disease Respiratory Tra... Neoplasm, Bronc... Carcinoma, Bron... | SHR-1210 | 18 Years - 80 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) | NCT01999985 | Lung Cancer Non-small Cell ... | Dasatinib - 1A Afatinib - 1A Dasatinib - 1B Afatinib - 1B | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | NCT04862780 | Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla... | BLU-945 osimertinib | 18 Years - | Blueprint Medicines Corporation | |
| Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer | NCT01594398 | Lung Cancer Non Small Cell ... Breast Cancer Estrogen Recept... | entinostat entinostat Erlotinib Erlotinib Exemestane Exemestane | 18 Years - 90 Years | Syndax Pharmaceuticals | |
| Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer | NCT02904954 | Carcinoma, Non-... | Durvalumab Durvalumab plus... | 18 Years - | Weill Medical College of Cornell University | |
| A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection | NCT03083743 | Non-small-cell ... | Recombinant hum... Placebo | 18 Years - 75 Years | Shanghai Gebaide Biotechnology Co., Ltd. | |
| Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC | NCT06376084 | Carcinoma, Non-... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... | 18 Years - | AstraZeneca | ||
| Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients | NCT02804100 | Carcinoma, Non-... Bronchial Neopl... Carcinoma, Bron... Lung Diseases Lung Neoplasms | 18 Years - | Wenzhou Medical University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
